Browse articles on EyeWorld.org. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.

Read more about the article Experts differ on corneal astigmatism correction in cataract surgery
Dual Scheimpflug image showing more than 3 D of WTR astigmatism on the anterior cornea and 0.65 on the posterior cornea (which has an ATR refractive effect) Source: Douglas Koch, M.D., and Wang Li, M.D.

Experts differ on corneal astigmatism correction in cataract surgery

Total corneal astigmatism correction during cataract surgery could be either by eliminating it or leaving slight with-the-rule astigmatism.

Comments Off on Experts differ on corneal astigmatism correction in cataract surgery

Cornea surgeons compare thin DSAEK and DMEK as options for endothelial keratoplasty procedures

When it comes to corneal endothelial disorders, endothelial keratoplasty has become popular with ophthalmologists worldwide, and many choose between DSEK and DMEK. DSEK seems to be the current preferred method, with developments in DMEK causing the technique to gain ground.

Comments Off on Cornea surgeons compare thin DSAEK and DMEK as options for endothelial keratoplasty procedures

Uveitis: Posterior synechiae, lens deposits, CME, prolonged post-op inflammation, and secondary glaucoma

Uveitis following cataract surgery increases the risk of cystoid macular edema (CME), posterior synechiae, and secondary glaucoma, all of which may lead to delayed visual recovery or permanent visual loss. It is important to make the distinction between patients with pre-existing uveitis who undergo cataract surgery and those with no history of intraocular inflammation who develop uveitis after surgery.

Comments Off on Uveitis: Posterior synechiae, lens deposits, CME, prolonged post-op inflammation, and secondary glaucoma
Read more about the article The non-surgical option for vitreoretinal diseases
A graphic of the ocriplasmin molecule Source: ThromboGenics

The non-surgical option for vitreoretinal diseases

Ocriplasmin (ThromboGenics) is a first-in-class small molecule delivered through an intravitreal injection that targets fibronectin, laminin, and type IV collagen fibers that adhere the vitreous to the retina. The goal is to create a clean separation of the posterior vitreous cortex and the inner limiting membrane of the retina, thus avoiding a vitrectomy.

Comments Off on The non-surgical option for vitreoretinal diseases